A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Manojkumar Bupathi, MD, MS, discussed his takeaways on physician decision-making for frontline metastatic renal cell carcinoma (RCC) treatment from a Case-Based Roundtable event.

A panelist discusses how four FDA-approved agents treat steroid-refractory cGVHD, including ibrutinib (65% response rate), ...

An expert discusses treatment goals for patients with EGFR-mutated advanced/metastatic NSCLC, how to approach combination therapy with high-risk patients, and how recent data has influenced their ...

An expert discusses the safety profiles of combination regimens, effective strategies for managing side effects, and how to weigh the potential for toxicity versus efficacy/benefits when discussing ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...